Abstract:Despite accounting for >90% of the surface area of the GI tract, the small intestine has historically been responsible for <5% of all GI cancers. Over time, however, the incidence of small intestinal cancer has increased while other GI cancers (eg., colorectal, gastric, etc.) have decreased. To help elucidate the cause of this increase, we investigated histology-specific incidence and mortality trends in small intestinal cancer. We used SEER-9 data (covering ~10% of the US population) to identify 4 histological categories of small intestinal cancers (adenocarcinoma, neuroendocrine, lymphoma, and sarcoma/gastrointestinal stromal tumor [GIST]) to assess trends in incidence. Because death certificates do not include histology information, incidence-based mortality (IBM) was used to assess histology-specific mortality trends. From 1976 to 2016, 22,082 patients were diagnosed with one of four histological types of small intestinal cancer (ICD-O-3 codes C17.0-17.9). The overall incidence of these cancers more than doubled, from 12.1 to 27.9 per million (absolute increase 15.8; 95% CI: 14.3-17.3), largely because of a nearly 4-fold growth in neuroendocrine tumor incidence: from 3.7 to 14.6 per million (absolute increase 10.9; 95%CI: 10.0-11.8). The proportion of patients with localized disease increased from 14.7% of cases in 1976 to 38.9% of cases in 2014. There was little concomitant change in neuroendocrine mortality (from 1.4 to 2.2 per million, absolute increase 0.8; 95%CI: 0.4-1.2). The histologic distribution changed from 30% neuroendocrine histology in 1976 to 52% in 2016. Duodenal neuroendocrine tumors grew particularly rapidly from 0.1 to 4.2 per million (absolute increase 4.1; 95% CI, 3.7-4.5). Adenocarcinoma incidence rose slightly, but in tandem with mortality. Deaths attributed to small intestinal cancer on death certificates were virtually indistinguishable from adenocarcinoma IBM, suggesting that deaths attributed to small intestinal cancer were, in fact, predominantly due to adenocarcinoma. Both incidence and mortality of lymphoma initially rose before declining, similar to that for non-Hodgkin's lymphomas in general. Despite a small increase in GIST incidence, mortality decreased by 40% (from 1.0 to 0.6 per million). In summary, cancers of the small intestine are being diagnosed more frequently. There was little change in the occurrence of adenocarcinoma or the ability to treat the disease. Treatment advances, however, were apparent in GIST and lymphoma as evidenced by improvements in population-based mortality. Neuroendocrine tumor incidence increased rapidly and substantially while mortality was relatively stable, a pattern consistent with overdiagnosis and/or better diagnosis of symptomatic, low-lethality disease. Overdiagnosis appeared particularly likely in early stage and (more accessible) duodenal tumors. Citation Format: Haley J. Yao, Claire Sokas, H. Gilbert Welch. The role of overdiagnosis & better diagnosis of low-lethality disease in the rising incidence of cancer of the small intestine [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl) nr 5909.

Non-specific presentation of metastatic small bowel adenocarcinoma with diagnostic challenges

Metastatic colon cancer of the small intestine diagnosed using genetic analysis: a case report

Gastrointestinal Hemorrhage Due to Ileal Metastasis from Primary Lung Cancer

Total obstruction of small intestine due to metastatic lung adenocarcinoma

An Unexpected Challenge: Marked Small Bowel Obstruction Arising From a Poorly Differentiated Metastatic Mucinous Adenocarcinoma of the Distal Ileum in a Risk-Free Healthy Patient

Abstract 5909: The role of overdiagnosis & better diagnosis of low-lethality disease in the rising incidence of cancer of the small intestine

Metastatic spread of primary lung adenocarcinoma to the small intestine: A case report

S4862 Multifaceted Diagnostic Approach for Unexplained Anemia in a Post Liver Transplant Patient With Metastatic Adenocarcinoma and Roux-en-Y Gastric Bypass

Duodenal adenocarcinoma at stage IV: A critical look at diagnostic pathways and treatment modalities

Acute Small Bowel Obstruction: a Rare Initial Presentation for the Metastasis of the Large-Cell Carcinoma of the Lung.

Obscure Bleeding from a Metastatic Small Bowel Tumor Diagnosed Using Motorized Spiral Enteroscopy: A Case Study and a Literature Review

[Duodenal bleeding due to metastasis from lung adenocarcinoma controlled by radiotherapy: A case report and literature review]

Gastrointestinal bleeding due to pancreatic metastasis of non-small cell lung cancer: A report of two cases and a literature review

Clinicopathological analysis of small intestinal metastasis from extra-abdominal/extra-pelvic malignancy

Atypical presentation of sigmoid carcinoma

Atypical age of onset of the small bowel adenocarcinoma – case report

Challenging diagnosis of a jejunal adenocarcinoma with ovarian metastasis: report of an unusual case

S4808 A Rare Case of Duodenal Adenocarcinoma in a 22-Year-Old

Adenocarcinoma of the appendix presenting as chronic small bowel obstruction: A case report

Lung carcinoma with small intestinal metastases and gastrointestinal bleeding: A rare case report

[The clinical characteristics of metastatic tumors in small intestine]